Opportunities to overcome underutilization of enhanced insulin delivery technologies in people with type 2 diabetes: a narrative review
Postgrad Med. 2024 Mar 18. doi: 10.1080/00325481.2024.2331417. Online ahead of print.ABSTRACTUse of innovative technologies such as continuous glucose monitoring (CGM) and insulin delivery systems have been shown to be safe and effective in helping patients with diabetes achieve significantly improved glycemic outcomes compared to their previous therapies. However, these technologies are underutilized in many primary care practices. This narrative review discusses some of the clinical and economic benefits of tubeless insulin delivery devices and discusses how this technology can overcome the main obstacles inherent to use...
Source: Postgraduate Medicine - March 18, 2024 Category: Internal Medicine Authors: Davida F Kruger Diana Isaacs Lucille Hughes Eden Miller Timothy S Bailey Source Type: research
Guideline-based management of metabolic dysfunction-associated steatotic liver disease in the primary care setting
CONCLUSIONS: Primary care providers are ideally placed to identify at-risk individuals, implement evidence-based interventions to prevent the development of fibrosis and cirrhosis, and effectively manage comorbidities. Equipping primary care providers with the necessary knowledge and tools to effectively manage MASLD/MASH may help to improve patient outcomes and reduce the burden of liver disease.PMID:38465573 | DOI:10.1080/00325481.2024.2325332 (Source: Postgraduate Medicine)
Source: Postgraduate Medicine - March 11, 2024 Category: Internal Medicine Authors: Alina M Allen Michael Charlton Kenneth Cusi Stephen A Harrison Kris V Kowdley Mazen Noureddin Jay H Shubrook Source Type: research
You may delay, but time will not. Beta cells lost are never found again: a case for timely initiation of basal insulin in type 2 diabetes
Postgrad Med. 2024 Mar 11. doi: 10.1080/00325481.2024.2328511. Online ahead of print.ABSTRACTSince its first use just over a century ago, insulin treatment has evolved dramatically, such that the molecules are physiologic in nature, and treatment can now closely resemble the natural hormone response over 24 hours. Newer, longer-acting basal insulin analogs have provided insulin therapies with improved characteristics and, therefore, ease of use, and can readily be incorporated as part of routine treatment for type 2 diabetes (T2D), but evidence suggests that insulin remains underused in people with T2D. We review the barri...
Source: Postgraduate Medicine - March 11, 2024 Category: Internal Medicine Authors: Susan Renda Jeffrey Freeman Source Type: research
Guideline-based management of metabolic dysfunction-associated steatotic liver disease in the primary care setting
CONCLUSIONS: Primary care providers are ideally placed to identify at-risk individuals, implement evidence-based interventions to prevent the development of fibrosis and cirrhosis, and effectively manage comorbidities. Equipping primary care providers with the necessary knowledge and tools to effectively manage MASLD/MASH may help to improve patient outcomes and reduce the burden of liver disease.PMID:38465573 | DOI:10.1080/00325481.2024.2325332 (Source: Postgraduate Medicine)
Source: Postgraduate Medicine - March 11, 2024 Category: Internal Medicine Authors: Alina M Allen Michael Charlton Kenneth Cusi Stephen A Harrison Kris V Kowdley Mazen Noureddin Jay H Shubrook Source Type: research
You may delay, but time will not. Beta cells lost are never found again: a case for timely initiation of basal insulin in type 2 diabetes
Postgrad Med. 2024 Mar 11. doi: 10.1080/00325481.2024.2328511. Online ahead of print.ABSTRACTSince its first use just over a century ago, insulin treatment has evolved dramatically, such that the molecules are physiologic in nature, and treatment can now closely resemble the natural hormone response over 24 hours. Newer, longer-acting basal insulin analogs have provided insulin therapies with improved characteristics and, therefore, ease of use, and can readily be incorporated as part of routine treatment for type 2 diabetes (T2D), but evidence suggests that insulin remains underused in people with T2D. We review the barri...
Source: Postgraduate Medicine - March 11, 2024 Category: Internal Medicine Authors: Susan Renda Jeffrey Freeman Source Type: research
Guideline-based management of metabolic dysfunction-associated steatotic liver disease in the primary care setting
CONCLUSIONS: Primary care providers are ideally placed to identify at-risk individuals, implement evidence-based interventions to prevent the development of fibrosis and cirrhosis, and effectively manage comorbidities. Equipping primary care providers with the necessary knowledge and tools to effectively manage MASLD/MASH may help to improve patient outcomes and reduce the burden of liver disease.PMID:38465573 | DOI:10.1080/00325481.2024.2325332 (Source: Postgraduate Medicine)
Source: Postgraduate Medicine - March 11, 2024 Category: Internal Medicine Authors: Alina M Allen Michael Charlton Kenneth Cusi Stephen A Harrison Kris V Kowdley Mazen Noureddin Jay H Shubrook Source Type: research
You may delay, but time will not. Beta cells lost are never found again: a case for timely initiation of basal insulin in type 2 diabetes
Postgrad Med. 2024 Mar 11. doi: 10.1080/00325481.2024.2328511. Online ahead of print.ABSTRACTSince its first use just over a century ago, insulin treatment has evolved dramatically, such that the molecules are physiologic in nature, and treatment can now closely resemble the natural hormone response over 24 hours. Newer, longer-acting basal insulin analogs have provided insulin therapies with improved characteristics and, therefore, ease of use, and can readily be incorporated as part of routine treatment for type 2 diabetes (T2D), but evidence suggests that insulin remains underused in people with T2D. We review the barri...
Source: Postgraduate Medicine - March 11, 2024 Category: Internal Medicine Authors: Susan Renda Jeffrey Freeman Source Type: research
Guideline-based management of metabolic dysfunction-associated steatotic liver disease in the primary care setting
CONCLUSIONS: Primary care providers are ideally placed to identify at-risk individuals, implement evidence-based interventions to prevent the development of fibrosis and cirrhosis, and effectively manage comorbidities. Equipping primary care providers with the necessary knowledge and tools to effectively manage MASLD/MASH may help to improve patient outcomes and reduce the burden of liver disease.PMID:38465573 | DOI:10.1080/00325481.2024.2325332 (Source: Postgraduate Medicine)
Source: Postgraduate Medicine - March 11, 2024 Category: Internal Medicine Authors: Alina M Allen Michael Charlton Kenneth Cusi Stephen A Harrison Kris V Kowdley Mazen Noureddin Jay H Shubrook Source Type: research
You may delay, but time will not. Beta cells lost are never found again: a case for timely initiation of basal insulin in type 2 diabetes
Postgrad Med. 2024 Mar 11. doi: 10.1080/00325481.2024.2328511. Online ahead of print.ABSTRACTSince its first use just over a century ago, insulin treatment has evolved dramatically, such that the molecules are physiologic in nature, and treatment can now closely resemble the natural hormone response over 24 hours. Newer, longer-acting basal insulin analogs have provided insulin therapies with improved characteristics and, therefore, ease of use, and can readily be incorporated as part of routine treatment for type 2 diabetes (T2D), but evidence suggests that insulin remains underused in people with T2D. We review the barri...
Source: Postgraduate Medicine - March 11, 2024 Category: Internal Medicine Authors: Susan Renda Jeffrey Freeman Source Type: research
Guideline-based management of metabolic dysfunction-associated steatotic liver disease in the primary care setting
CONCLUSIONS: Primary care providers are ideally placed to identify at-risk individuals, implement evidence-based interventions to prevent the development of fibrosis and cirrhosis, and effectively manage comorbidities. Equipping primary care providers with the necessary knowledge and tools to effectively manage MASLD/MASH may help to improve patient outcomes and reduce the burden of liver disease.PMID:38465573 | DOI:10.1080/00325481.2024.2325332 (Source: Postgraduate Medicine)
Source: Postgraduate Medicine - March 11, 2024 Category: Internal Medicine Authors: Alina M Allen Michael Charlton Kenneth Cusi Stephen A Harrison Kris V Kowdley Mazen Noureddin Jay H Shubrook Source Type: research
You may delay, but time will not. Beta cells lost are never found again: a case for timely initiation of basal insulin in type 2 diabetes
Postgrad Med. 2024 Mar 11. doi: 10.1080/00325481.2024.2328511. Online ahead of print.ABSTRACTSince its first use just over a century ago, insulin treatment has evolved dramatically, such that the molecules are physiologic in nature, and treatment can now closely resemble the natural hormone response over 24 hours. Newer, longer-acting basal insulin analogs have provided insulin therapies with improved characteristics and, therefore, ease of use, and can readily be incorporated as part of routine treatment for type 2 diabetes (T2D), but evidence suggests that insulin remains underused in people with T2D. We review the barri...
Source: Postgraduate Medicine - March 11, 2024 Category: Internal Medicine Authors: Susan Renda Jeffrey Freeman Source Type: research
Guideline-based management of metabolic dysfunction-associated steatotic liver disease in the primary care setting
CONCLUSIONS: Primary care providers are ideally placed to identify at-risk individuals, implement evidence-based interventions to prevent the development of fibrosis and cirrhosis, and effectively manage comorbidities. Equipping primary care providers with the necessary knowledge and tools to effectively manage MASLD/MASH may help to improve patient outcomes and reduce the burden of liver disease.PMID:38465573 | DOI:10.1080/00325481.2024.2325332 (Source: Postgraduate Medicine)
Source: Postgraduate Medicine - March 11, 2024 Category: Internal Medicine Authors: Alina M Allen Michael Charlton Kenneth Cusi Stephen A Harrison Kris V Kowdley Mazen Noureddin Jay H Shubrook Source Type: research
You may delay, but time will not. Beta cells lost are never found again: a case for timely initiation of basal insulin in type 2 diabetes
Postgrad Med. 2024 Mar 11. doi: 10.1080/00325481.2024.2328511. Online ahead of print.ABSTRACTSince its first use just over a century ago, insulin treatment has evolved dramatically, such that the molecules are physiologic in nature, and treatment can now closely resemble the natural hormone response over 24 hours. Newer, longer-acting basal insulin analogs have provided insulin therapies with improved characteristics and, therefore, ease of use, and can readily be incorporated as part of routine treatment for type 2 diabetes (T2D), but evidence suggests that insulin remains underused in people with T2D. We review the barri...
Source: Postgraduate Medicine - March 11, 2024 Category: Internal Medicine Authors: Susan Renda Jeffrey Freeman Source Type: research
Prognostic significance of body mass index and serum albumin as the indicators of nutritional status in small cell lung cancer
CONCLUSION: Even though BMI and serum albumin showed no prognostic value in SCLC patients treated with chemotherapy, PS was found to be the most significant prognostic factor in both LD- and ED-SCLC stages.PMID:38456321 | DOI:10.1080/00325481.2024.2328512 (Source: Postgraduate Medicine)
Source: Postgraduate Medicine - March 8, 2024 Category: Internal Medicine Authors: Faruk Tas Ak ın Ozturk Kayhan Erturk Source Type: research